Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2010 | 1 |
2014 | 1 |
2024 | 0 |
Search Results
2 results
Results by year
Filters applied: . Clear all
Page 1
In vivo neutralization of unfractionated heparin and low-molecular-weight heparin by a novel salicylamide derivative.
Clin Appl Thromb Hemost. 2010 Aug;16(4):377-86. doi: 10.1177/1076029610366439. Epub 2010 May 11.
Clin Appl Thromb Hemost. 2010.
PMID: 20460347
Free article.
The objective of this investigation is to characterize the effectiveness of a novel salicylamide-derived heparin antagonist, PMX 60056, in neutralizing the antithrombotic and bleeding effects of UFH and LMWHs. ...These results suggest that PMX 60056 ma …
The objective of this investigation is to characterize the effectiveness of a novel salicylamide-derived heparin antagonist, PMX 6 …
A 1-year drug utilization evaluation of protamine in hospitalized patients to identify possible future roles of heparin and low molecular weight heparin reversal agents.
Mahan CE.
Mahan CE.
J Thromb Thrombolysis. 2014 Apr;37(3):271-8. doi: 10.1007/s11239-013-0927-7.
J Thromb Thrombolysis. 2014.
PMID: 23653171
Availability of new reversal agents for approved anticoagulants and those in development may improve patient safety and care. Delparantag (PMX-60056) is a novel small molecule that shows ability to neutralize the anticoagulation effects of UFH and LMWH in ani …
Availability of new reversal agents for approved anticoagulants and those in development may improve patient safety and care. Delparantag …
Item in Clipboard
Cite
Cite